Annual Report 2006 - Boehringer Ingelheim

More documents

Recommendations

Info

Financial Highlights Boehringer Ingelheim group of companies Amounts in millions of EUR, unless otherwise indicated 2006 2005 change Net sales 10,574 9,535 11 % by region Europe 31 % 33 % Americas 51 % 48 % Asia, Australasia, Africa 18 % 19 % by business area Human Pharmaceuticals 96 % 96 % Animal Health 4 % 4 % Research and development 1,574 1,360 16 % Personnel costs 2,836 2,671 6 % Average number of employees 38,428 37,406 3 % Operating income 2,140 1,923 11 % Operating income as % of sales 20.2 % 20.2 % Income after taxes 1,729 1,514 14 % Income after taxes as % of sales 16.4 % 15.9 % Shareholders’ equity 5,175 4,609 12 % Return on shareholders’ equity 37.4 % 34.2 % Cash flow 2,317 2,069 12 % Investments in tangible assets 596 532 12 % Depreciation of tangible assets 419 439 -5 % Top 5 products — Prescription Medicines Net sales 2006 in millions of EUR change spiriva® 1,381 45.2 % micardis® 967 33.6 % flomax® 922 27.8 % combivent® 671 19.6 % mobic® 579 -31.8 % Top 5 products — Consumer Health Care Net sales 2006 in millions of EUR change dulcolax® 122.0 6.2 % mucosolvan® 108.3 18.6 % pharmaton® 95.6 8.2 % buscopan® 71.2 19.6 % bisolvon® 67.1 0.4 %
Contents 1 Value Through Innovation 2 The Shareholders’ Perspective 4 Key Aspects of 2006 9 Our Caring Culture 10 “There is help” 14 Our People 18 Caring for our Neighbours 22 Our Environment & Employee Safety 27 Our R & D Drive 28 Targeting tomorrow’s therapies 32 Our R & D Strategy 38 Our Expertise in Landmark Studies 40 From Mind to Man – The R & D Process 42 New Biological Entities (NBE) 43 Biomarker & Pharmacogenetics 45 Serving Patients * 46 “I wake up refreshed ...” 49 Human Pharmaceuticals 60 “My recovery came fast” 78 “Now I know how to keep them under control” 80 From Plant to the Pharmacy – The buscopan® Story 81 Consumer Health Care 84 Our friend Tom 87 Animal Health 91 Our Customer Orientation 92 Biopharmaceuticals – How Innovations are Made 95 Pharmaceuticals Production and Pharma Chemicals 97 Counterfeits – A Real Threat for Patients 99 Group Management Report 115 Consolidated Financial Statements 2006 116 Overview of the Major Consolidated Companies 118 Consolidated Balance Sheet 119 Consolidated Profit and Loss Statement 120 Cash Flow Statement 121 Statement of Changes in Group Equity 122 Notes to the Consolidated Financial Statements 2006 140 Auditor’s Report 142 Glossary Flap Comparison of Balance Sheet / Financial Data 1997–2006 Our friend Tom Every year, about 10 % of all horses suffer from equine colic, a disease that can prove life-threatening. [page 84] “Now I know how to keep them under control” Abdominal pains and cramps, a widespread ailment, is more common in women than in men and can affect people still in their teens. [page 78] * The patient reports are authentic reports which refer to personal experience only. Please acknowledge that other patients may experience different treatment results. Individual treatment schemes have always to be discussed between patient and physician case by case. “There is help“ In Kenya, about 50,000 newborn babies a year are estimated to acquire HIV from their infected mothers. Worldwide UNAIDS talks of 2.3 million cases of AIDS-diseased children. [page 10] Targeting tomorrow’s therapies Focusing on both biopharmaceutical and small molecule drugs, Boehringer Ingelheim has embarked on a major drive to discover and develop new cancer drugs. [page 28] “My recovery came fast” Stroke is a serious disease. It is the third leading cause of death after heart disease and cancer and the most important reason for medical disability. [page 60] “I wake up refreshed ...” Hypertension is not only an unpleasant condition that keeps people from doing what the things they like. It is also a serious cardiovascular risk that can be the precursor to stroke and heart attack. [page 46] please turn over
Page 1: Value through Innovation Annual Rep
Page 5 and 6: The Shareholders’ Perspective Dea
Page 7 and 8: Key Aspects of 2006 2006 was again
Page 9 and 10: This growth was clearly restrained
Page 11 and 12: Shareholders’ Committee Dr Heribe
Page 13 and 14: “There is help” “The woman wh
Page 15 and 16: 1 continued from page 10 A Kenyan m
Page 17 and 18: 1 Our people In pursuing our vision
Page 19 and 20: Company childcare enters new territ
Page 21 and 22: 1 Caring for our neighbours We are
Page 23 and 24: 0 Children from St Margaret Clither
Page 25 and 26: Our environment & employee safety A
Page 27 and 28: thanks to the use of the wood-fired
Page 29 and 30: Our goals We shall continue to inve
Page 31 and 32: Targeting tomorrow’s therapies Th
Page 33 and 34: 0 continued from page 28 “Boehrin
Page 35 and 36: Our R & D strategy Research and dev
Page 37 and 38: Ridgefield, USA Cardiovascular, imm
Page 39 and 40: Vienna, Austria Oncology Boehringer
Page 41 and 42: Our expertise in landmark studies L
Page 43 and 44: From mind to man - the R & D proces
Page 45 and 46: New biological entities (NBE) One o
Page 47 and 48: The development of our businesses W
Page 49: Rin Fujima, Kyoto, Japan, suffers f
Page 52 and 53:
Human Pharmaceuticals Branded presc
Page 54 and 55:
cal exercise capacity and the reduc
Page 56 and 57:
“Like a great round of golf“
Page 58 and 59:
gives patients a better chance of g
Page 60 and 61:
aptivus® was launched in the USA i
Page 62 and 63:
enzymes, such as the HCV serine pro
Page 64 and 65:
Børge Madsen, Copenhagen, Denmark.
Page 66 and 67:
Cardiovascular diseases Despite sig
Page 68 and 69:
actilyse® is the first and only th
Page 70 and 71:
fibrillation in some 40 countries i
Page 72 and 73:
Treatment modalities used to reliev
Page 74 and 75:
HuCAL antibody directed against a c
Page 76 and 77:
hand, the end of exclusivity in Eur
Page 78 and 79:
Generic Prescription Medicines The
Page 80 and 81:
Ben Venue - a world leader in steri
Page 82 and 83:
Mara Lovera, Buenos Aires, Argentin
Page 84 and 85:
Consumer Health Care Our Consumer H
Page 86 and 87:
Switching reinforces the trend towa
Page 88 and 89:
Alexander (left) and Christopher pl
Page 90 and 91:
Animal Health The sound progress of
Page 92 and 93:
located, trained and placed with fi
Page 94 and 95:
Our Customer Orientation Our custom
Page 96 and 97:
On a biopharmaceutical compound’s
Page 98 and 99:
Pharmaceuticals Production Our Phar
Page 100 and 101:
Counterfeits - a real threat for pa
Page 102 and 103:
Group Management Report 2006
Page 104 and 105:
companies lost their patent protect
Page 106 and 107:
To summarise, we see the success of
Page 108 and 109:
Production Production sites belongi
Page 110 and 111:
In the area of HIV/AIDS therapy, we
Page 112 and 113:
only 2 %. The region’s overall ne
Page 114 and 115:
of the cash flow, which rose by EUR
Page 116 and 117:
Report on expected developments The
Page 118 and 119:
Consolidated Financial Statements 2
Page 120 and 121:
C. H. Boehringer Sohn Grundstücksv
Page 122 and 123:
C. H. Boehringer Sohn, Ingelheim Co
Page 124 and 125:
C. H. Boehringer Sohn, Ingelheim St
Page 126 and 127:
The following subsidiaries were exe
Page 128 and 129:
2 Accounting and evaluation methods
Page 130 and 131:
3 Notes to the consolidated balance
Page 132 and 133:
3.3 Financial assets (in millions o
Page 134 and 135:
Pension provisions Boehringer Ingel
Page 136 and 137:
4 Notes to the consolidated profit
Page 138 and 139:
4.7 Holding income (in millions of
Page 140 and 141:
Other mandatory disclosures accordi
Page 142 and 143:
Derivative financial instruments at
Page 144 and 145:
With the following exception, our a
Page 146 and 147:
Product name Active ingredient Indi
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Comparison of Balance Sheets/ Finan
show all

Annual Report 2006 - Boehringer Ingelheim

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?